NovaBay Pharmaceuticals, Inc.
NBY · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | -$0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 8.1% | – | – | 65% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -255.5% | – | – | -51.8% |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -248.2% | – | – | -52.5% |
| EPS Diluted | -0.22 | -0.33 | 1.42 | -0.27 |
| % Growth | 33.3% | -123.2% | 625.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |